Preparation and evaluation of sustained-release matrix tablets based on metoprolol and an acrylic carrier using injection moulding by Quinten, Thomas et al.
  
biblio.ugent.be 
 
The UGent Institutional Repository is the electronic archiving and dissemination platform for all 
UGent research publications. Ghent University has implemented a mandate stipulating that all 
academic publications of UGent researchers should be deposited and archived in this repository. 
Except for items where current copyright restrictions apply, these papers are available in Open 
Access. 
 
This item is the archived peer-reviewed author-version of: Preparation and evaluation of 
sustained-release matrix tablets based on metoprolol and an acrylic carrier using injection 
moulding 
Authors: Quinten T., Andrews G.P., De Beer T., Saerens L., Bouquet W., Jones D.S., Hornsby 
P., Remon J.P., Vervaet C.            
In: AAPS Pharmscitech, 13(4), 1197-1211 (2012)  
 
Optional: link to the article  
 
To refer to or to cite this work, please use the citation to the published version: 
Authors (year). Title. journal Volume(Issue)  page-page. Doi 10.1208/s12249-012-9848-6 
Preparation and evaluation of sustained-release matrix tablets 
based on metoprolol and an acrylic carrier using injection moulding. 
Quinten T.a, Andrews G.P.b, De Beer T.c, Saerens L.c, Bouquet W.a, Jones D.S.b, 
Hornsby P.d , Remon J.P. a and Vervaet C.a* 
 
a  Laboratory of Pharmaceutical Technology, Ghent University, Harelbekestraat 72, B-9000 
Ghent, Belgium 
b  School of Pharmacy, Queen’s University Belfast, Lisburn Road 97, Belfast BT9 7BL, United 
Kingdom 
c Laboratory of Pharmaceutical Process Analytical Technology, Ghent University, Harelbekestraat 
72, B-9000 Ghent, Belgium 
d School of Mechanical and Aerospace Engineering, Queen’s University Belfast, Stranmillis Road, 
Belfast BT9 5AG, United Kingdom 
  
* Corresponding author: 
Prof. Dr. Chris Vervaet 
Laboratory of Phamaceutical Technology 
University of Ghent 
Harelbekestraat 72, 9000 Gent 
Belgium 
Phone: 003292648069 
Fax: 003292228236 
E-mail: Chris.Vervaet@ugent.be 
1. Introduction 
Injection moulding (IM) originated from, and has been widely used, within the plastic 
processing industry, but has only recently been proposed as a novel drug delivery 
technology. IM is capable of mass-producing intricate polymeric parts with the aid of heat 
and pressure, in a wide variety of shapes with high dimensional precision. During the 
process, polymeric materials, functional excipients and active agents are gradually mixed 
and heated, and transferred by means of an injection step into a shape-specific mould. After 
sufficient cooling, the mould can be opened to recover the formed part. 
Although IM has been routinely used within the plastics processing industry, it has been 
largely ignored as a drug delivery technology. Given the large number of advantages this 
process offers over traditional pharmaceutical manufacturing techniques, IM is now 
receiving increasing interest for biomedical and pharmaceutical applications (1-3). In this 
respect, injection moulding has been applied successfully to provide modified release drug 
delivery platforms via the homogeneous embedding of drug particles in release-modifying 
polymers. In these studies, drug release from IM tablets was sustained using ethylcellulose 
as matrix former and using various hydrophilic fillers (hydroxypropylmethylcellulose, low-
substituted hydroxypropylcellulose, polyethylene oxide and xanthan gum) to control the 
release rate. Only the use of xanthan gum resulted in zero-order release, and for all these 
systems drug was released by a combination of polymer swelling, Fickian diffusion and 
matrix erosion (4-7). In addition, hot melt methods (i.e. hot-melt extrusion and injection 
moulding) offer the possibility to disperse active pharmaceutical ingredients in a polymeric 
carrier in a highly controlled manner, yielding solid dispersions/solutions (8). These dosage 
forms aim at an improved dissolution rate and hence bioavailability of poorly soluble drugs; 
an area of increasing importance (9). Moreover, hot-melt methods offer a potential solution 
to problems encountered with traditional methods for preparing solid solutions/dispersions: 
the process itself inherently allows a better monitoring and standardisation, scale-up is more 
easily achieved, the complexities of solvent residuals and the need for solvent-proof 
equipment are negated (1). A further advantage of IM is the distinct possibility of mass 
producing drug delivery platforms in a single step, thus avoiding the need for additional 
processing steps; a problem often encountered with hot-melt extrusion. 
Although IM has significant potential as a novel drug delivery technology, a paradigm shift in 
pharmaceutical solid dosage form manufacturing will require a fundamental and extensive 
evaluation of this process to determine the effects of both process and formulations factors 
on product performance. Although IM is gaining increasing interest, the current scientific 
literature contains only a limited number of studies reporting the use of IM; mostly 
conducted by our group. In order to truly implement IM as a drug delivery technology, this 
deficit must be urgently addressed. The aim of this study was to evaluate the feasibility of 
polymethacrylates (Eudragit RL and RS) as matrix carriers in the development of IM 
sustained release matrix tablets containing different salt forms of metoprolol. In so doing we 
aim to complement the current literature with novel information relating to the use of melt 
processed Eudragit RL/RS platforms (10, 11). The influence of process temperature, 
plasticizer concentration and salt form of metoprolol (tartrate, fumarate and succinate) on 
the ease of processing and the in vitro drug release properties, were evaluated. Injection-
moulded tablets were characterized with respect to polymer/drug miscibility, solid-state 
properties and physical stability. Finally, the in vivo performance of moulded tablets was 
determined after administration to dogs. 
 
 
2. Material and methods 
2.1. Materials 
Metoprolol tartrate (MPT, EQ Esteve, Spain) was selected as model drug. Other salts of 
metoprolol included metoprolol succinate (MPS) and fumarate (MPF) (Polydrug 
Laboratories, India). Eudragit® RL PO and RS PO were kindly donated by Evonik (Darmstadt, 
Germany). Triethyl citrate was purchased from Sigma (TEC, USA). Slow-Lopressor® 200 
Divitabs containing 200 mg metoprolol tartrate were purchased from Sankyo Pharma 
(Belgium). 
 
2.2. Production and storage of injection-moulded tablets 
An overview of the different formulations with respect to their processing conditions is given 
in Table 1. In a pre-plasticizing step triethyl citrate was mixed with Eudragit RL and RS using 
mortar and pestle, followed by homogenization in planetary mixer for 15 min at 90 rpm 
(Kenwood Major Classic, UK). This mixture was stored overnight to allow the plasticizer to 
interact with the polymer. Metoprolol was blended with (un)plasticized polymer for 15 min 
in a tumbling mixer prior to melt processing. These mixtures were extruded using a co-
rotating twin-screw mini-extruder (Thermo scientific Haake MiniLab II Micro Compounder, 
Thermo Scientific, Germany) at a screw speed of 90 rpm employing a cylindrical die with a 
diameter of 2 mm. The molten extrudates were collected in a heated reservoir and 
immediately shaped into tablets using a lab-scale injection moulder (Haake MiniJet System, 
Thermo Electron, Germany) operating at the same temperature as the extruder. An injection 
pressure of 800 bar during an injection phase of 10 seconds followed by an after pressure of 
600 bar, applied for a period 5 seconds, was used to prepare the matrix tablets. The 
temperature of the mould was set at 20 °C. After cooling, biconvex tablets (diameter: 10 
mm/ height: 5 mm) with a mass of approximately 375 mg were obtained.  
In order to produce injection-moulded bars for dynamic mechanical testing and thermal 
analysis, the formulations were pre-compounded using a Thermo Haake twin screw extruder 
(Prism Eurolab 16 twin extruder, Thermo Scientific, Germany). Cooled extruded strands were 
cut into pellets (1-2 mm) via an in-line pelletiser (Prism Varicut 16 pelletiser, Thermo 
Scientific, Germany). Subsequently, these pellets were fed into an injection-moulding 
machine (Rondol High force 5, UK), equipped with a specific die (set at room temperature) to 
produce IM bars (length: 50.0 mm, width: 8.2 mm, height: 3.3 mm).  
Tablets were stored in open vials at 25°C ± 2°C/ 60% RH ± 5% for 12 months protected from 
light to determine the physical stability of the drug via thermal analysis. 
 
2.3. In vitro drug release 
Dissolution testing (n=3, each vessel containing one tablet) was performed using Apparatus 
2 (USP27) on a VanKel VK7010 dissolution tester combined with a VK 8000 automatic 
sampling station (VanKel Industries, USA). Since Eudragit RL and RS offer a pH-independent 
drug release and preliminary work showed that MPT, MPF and MPS release was not 
influenced by pH (data not shown), demineralized water (900 ml) was used as dissolution 
medium. The paddle speed was set at 50 rpm, while the temperature of the medium was 
maintained at 37 ± 0.5 °C. Samples of 5 mL were withdrawn at specific time points (0.5, 1, 2, 
4, 6, 8, 12, 16, 20 and 24 hours without media replacement) and spectro-photometrically 
assessed by means of a double beam spectrophotometer (UV-1650PC, Shimadzu, Belgium), 
(λmax MPT, MPS and MPF was 222, 222 and 220 nm respectively). The MPT, MPF or MPS 
content in the samples was determined by linear regression. The drug release kinetics were 
determined by finding the best fit between the experimental data (amount drug released vs. 
time) and kinetic models for zero-order, first-order release and the semi-empirical 
Korsmeyer-Peppas model as described by Quinten et al. (2009) (3). 
 
2.4. Liquid uptake, swelling and erosion  
Tablets (n=3) were introduced into the dissolution medium and subjected to a dissolution 
test under the same conditions as described above. At predetermined time intervals, the 
tablets were withdrawn from the medium and weighed after excessive water was gently 
removed from the surface with paper towel. The liquid uptake, expressed as percentage 
weight gain of the total polymer content, (Eq. 1) was calculated from the original weight, 
taking the amount of drug released at that particular time into account.  
 % Liquid uptake = (W w− DRt )− (W i− DR0) (W i− DR0)  x 100   (Eq. 1) 
 
with Ww the weight of the matrix tablet at time t, Wi the initial weight of the tablet before 
immersion (time 0), DR0 the amount of drug in the tablet at time 0 and DRt the amount of 
drug in the tablet at time t. 
 
The radial and axial swelling of the matrices during dissolution was determined by measuring 
the individual diameter and height of the tablets using an electric digital caliper (Bodson, 
Belgium). In addition, the degree of erosion (expressed as percentage loss of polymer 
content) (Eq. 2) was determined based on the weight difference between oven-dried 
matrices (40°C, 72 h) and the initial weight of the tablet, taken the amount of drug released 
at each time point into account. 
% Erosion = (W i− DR0)− (W d− DRt ) (W i− DR0)  x 100    (Eq. 2) 
 
with Wd the dry weight of the matrix tablet at time t, Wi the initial weight of the tablet 
before immersion (time 0), DR0 the amount of drug in the tablet at time 0 and DRt the 
amount of drug in the tablet at time t. 
 
2.5. X-ray diffraction  
The X-ray patterns were determined using a D5000 Cu Kα diffractor (λ = 0.154 nm) (Siemens, 
Germany) with a voltage of 40kV and current of 40mA in the angular range of 10° < 2θ < 60° 
using a step scan mode (step width = 0.02°, counting time = 1s/step). To analyze crystallinity, 
X-ray diffraction was performed on the different individual components as well as on 
physical mixtures and IM tablets. 
 
2.6. Scanning electron microscopy and hot-stage microscopy 
Scanning electron microscopy was used to study the morphology of the tablet surface. 
Tablets were coated with platinum by means of a sputter coater (Auto Fine Coater, JFC-
1300, Jeol, Japan). Photomicrographs were taken with a scanning electron microscope (Jeol 
JSM 5600 LV, Jeol, Japan). A polarized-light microscope (Eclipse E400, Nikon, Japan) 
equipped with hot stage (LTS350, TP94, Linkam Scientific Instruments, England), digital 
camera (Digital Slight DS-L1, Nikon, Japan) and image analysis program ((NIS-Elements Basic 
Research 2.30, Nikon, Japan) was used to investigate the drug/polymer miscibility. Cross-
polarisation was applied to investigate crystallinity. 
 
2.7. Thermal analysis 
Thermal analysis was done using a differential scanning calorimeter (Q2000 DSC, TA 
Instruments, UK) equipped with a refrigerated cooling system. The flow rate of dry nitrogen 
gas was 150 mL/min. Samples (n=3; 5-10 mg) were run in hermetically sealed aluminum 
pans supplied by TA Instruments (Leatherhead, UK). Temperature and enthalpic calibration 
was done using indium as a standard. In order to determine the melt endotherm onset 
temperature (Tmo), melting point (Tm), and heat of fusion (ΔH) of the different individual 
components, physical mixtures and tablets, samples (5-10 mg) were cooled to -50°C, held 
isothermal for 5 min and heated to 180°C at a linear heating rate of 10°C/min.  
Since the glass transition temperature was masked by an enthalpic relaxation endotherm on 
analysis with conventional DSC, modulated temperature DSC (MTDSC) was used to study the 
Tg of the individual components and physical mixtures according to a 3 cycle analysis 
(heating, cooling, heating) from -50 to 180°C. Injection-moulded bars were only subjected to 
1 cycle. MTDSC was performed using a TA instruments Q2000 DSC. Samples (n=3; ± 5mg) 
were sealed in Tzero aluminium pans with lid. The DSC was cooled to -50°C, equilibrated for 
5 min, followed by heating at an underlying heating rate of 2°C per minute, for which the 
temperature was modulated with an oscillation of 2°C every 60 seconds. The results were 
analyzed using the TA Instruments Universal Analysis 2000 Software. 
The experimental values of the glass transition temperature can be compared with 
calculated theoretical values to evaluate the miscibility of drug and excipients using the 
Gordon-Taylor equation (12). This relationship states that if drug and polymer are miscible, 
the mixture will show a single Tg that ranges between the Tg of pure components and 
depends on the relative portion of each component: 
 𝑇𝑇𝑔𝑔 = 𝑇𝑇𝑔𝑔1 𝑤𝑤1+ 𝑇𝑇𝑔𝑔2 𝐾𝐾 𝑤𝑤2 𝑤𝑤1+ 𝐾𝐾 𝑤𝑤2    
 
For which Tg1 and Tg2 are the glass transition temperatures of the metoprolol salt and 
Eudragit RL, respectively, w1 and w2 are the weight fractions of metoprolol and Eudragit in 
the dispersion, and K is a constant that can be estimated using the Simha-Boyer rule (13): 
𝐾𝐾 ≅  𝜌𝜌1𝑇𝑇𝑔𝑔1
𝜌𝜌2𝑇𝑇𝑔𝑔2  
With ρ1 and ρ2 the true densities of the respective metoprolol salt and Eudragit RL as 
determined by means of helium pycnometry (AccuPyc 1330, Micromeritics Instruments, 
USA). Since the Gordon-Taylor addresses the densities of amorphous components, the 
density of amorphous metoprolol salts was estimated from the true density of their 
respective crystalline counterpart, reduced by 5% (14). 
 
2.8. Dynamic mechanical analysis 
A Perkin-Elmer DMA 8000 Dynamic Mechanical Analyser was used to study the glass 
transition temperature of injection-moulded bars (n=3) in order to confirm and verify the 
results obtained with MTDSC. Experiments were performed by the application of a sinusoidal 
force resulting in a deformation of 10 µm at a frequency of 1 Hz. The amplitude of 
deformation, force and phase shift were recorded on bars clamped using a dual cantilever 
bending mode. The samples were cooled to -50°C at the start of the experiment and the 
temperature was ramped to 100°C at a rate of 3°C/min. The dynamic parameters, loss 
modulus (G’’) and storage modulus (G’), were recorded as a function of temperature and 
time, and tan δ (G’’/G’) was used to determine the Tg of the moulded bars.  
 
2.9. Three-dimensional solubility parameters 
Three-dimensional solubility parameters were calculated using SPWin (Version 2.1, 
Breitkreutz), utilizing an advanced parameter set combining the group contribution methods 
of Fedor and Van Krevelen/Hoftyzer, which was optimized by Breitkreutz (15). For polymeric 
excipients, determination of the solubility parameter was based on the average molecular 
weight. The solubility parameters of Eudragit RL and RS were compared to those of the APIs 
by observing the relative difference in the total solubility (δtotal), as well as partial Hansen 
solubility parameters (δd: contribution from dispersive forces, δp: contribution from polar 
forces, δh: contribution from hydrogen bonding).  
 
2.10. NIR and Raman spectroscopy 
Diffuse reflectance NIR spectra of physical mixtures, extrudates and injection moulded 
tablets containing Eudragit (RL or RS) and a metoprolol salt (MPT, MPF or MPS) were 
collected off-line, using a Fourier-Transform NIR spectrometer (Thermo Fisher Scientific, 
Belgium), and Nicolet Antaris II near-IR analyzer equipped with an InGaAS detector and a 
quartz halogen lamp. Each spectrum was collected in the 10000 – 4500 cm-1 region with a 
resolution of 8 cm-1 and averaged over 16 scans. Data analysis was performed using the 
Result software (Version 3.0, Thermo Fisher Scientific, Belgium), SIMCA-P+ (version 12.0.1.0, 
Umetrics, Sweden), and Matlab (The Mathworks, version 7.7). All spectra were pre-
processed using multiplicative signal correction (MSC), combined with smoothing of the 
spectra. 
Raman spectra of physical mixtures, extrudates and injection-moulded tablets containing 
Eudragit (RL or RS) and a metoprolol salt (MPT, MPF or MPS) were collected off-line using a 
Raman Rxn1 spectrometer (Kaiser Optical Systems, Ann Arbor, MI, USA), equipped with an 
air-cooled CCD detector. The laser wavelength was the 785 nm line from a 785 nm Invictus 
NIR diode laser. All spectra were recorded with a resolution of 4 cm-1 and an exposure time 
of 2 seconds, using a laser power of 400 mW. Data collection and data transfer were 
automated using the HoloGRAMSTM data collection software, the HoloREACTTM reaction 
analysis and profiling software, the Matlab software (version 7.1, The MathWorks Inc., 
Natick, MA) and SIMCA-P+ (version 12.0.1.0, Umetrics, Umeå, Sweden). The analyzed 
spectral region was 0 – 1800 cm-1, since this region contained all useful drug and polymer 
information. Prior to analysis, mean centering, standard normal variate pre-processing and 
smoothing were applied on the spectra. 
 
2.11. In vivo study 
All procedures were performed in accordance with the guidelines and after approval by the 
Ethics Committee of the Institute for Agricultural and Fisheries Research (ILVO) (Merelbeke, 
Belgium). The following formulations were administered during the in vivo evaluation: a) 
injection-moulded tablet containing 30% w/w MPT with 70% Eudragit RS (formulation F1, 
MPT dose administered: 110 mg); b) injection-moulded tablet containing 50% w/w MPT, and 
50% Eudragit RS (formulation F2, MPT dose administered: 186 mg); c) ½ tablet Slow-
Lopressor® 200 Divitabs® (reference formulation Fref, MPT dose administered: 100 mg). Since 
the size of the moulded tablets was fixed (due to the specific dimensions of the mould) and 
as the MPT/Eudragit RS-ratio was constant for the formulations selected for the in vivo 
study, different MPT doses were administered during the in vivo study. However, the 
pharmacokinetic profile was normalised for administered dose as linear pharmacokinetics 
have been reported for MPT in a dose range between 50 and 400 mg (16). All formulations 
were administered to male mixed-breed dogs (weight: 20-40 kg) in a cross-over sequence 
with a wash-out period of at least 8 days. Dogs were fasted 12 hours prior to the start of the 
experiments; however water was available ad libitum during the course of the experiment. 
Samples were collected in dry heparinised tubes at 0.5, 1, 2, 4, 6, 8, 12 and 24 hours after 
tablet intake followed by centrifugation at 1500g for 5min. No food was given to the dogs 
during the initial 24 hours of the test. Metoprolol tartrate plasma concentrations were 
determinate by a validated HPLC-fluorescence method (17, 2). The method was specific, 
linear (0.05-3.0 µg/mL, R2: 0.9972), precise: the intra-assay precision was 3.7-10.5% (within-
day repeatability), and the intermediated precision was 1.7-11.6% (between-day 
repeatability). The method was accurate and 79.3-85% of MPT was recovered. The limit of 
detection was 0.03 µg/mL and the limit of quantification was 0.10 µg/mL. 
 
2.12. Data analysis 
The peak plasma concentration (Cmax), the extent of absorption (AUC0-24h) and the time 
needed to reach the highest plasma-level (Tmax) were calculated using the MW-Pharm 
Program version 3.0 (Mediware 1987-1991, Utrecht, The Netherlands). AUC0-24h was 
calculated using logarithmic and linear trapezoidal rules. The relative bioavailability (Frel, 
expressed in %) was calculated as the AUC0-24h ratio between the test and the reference 
formulation (Fref), normalised for drug dose.  
The effect of the formulation on the bioavailability was statistically evaluated by repeated-
measures ANOVA (univariate analysis). To compare the effects of the different treatments 
on the pharmaco-kinetic parameters, a multiple comparison among pairs of means was 
performed using a Bonferroni post-hoc test with p<0.05 as significance level. The sphericity 
of covariances was tested with Mauchly’s test. If the assumption of sphericity was not 
fulfilled, the Huynh-Feldt correction was performed. All analyses were performed using SPSS 
17 (SPSS Inc., USA). 
3. Results and discussion 
3.1. Processability of injection-moulded Eudragit RL/RS formulations 
Eudragit® RL and RS are thermoplastic water-insoluble methacrylic ester copolymers, 
containing different quantities of quaternary ammonium groups (10% and 5% functional 
ammonium groups, respectively), which provide these polymers a pH-independent water 
permeability. These polymers are frequently used for sustained release applications such as 
coating, pellets, films or tablets, and their thermoplastic properties make them good 
candidates for melt processing. An overview of the different formulations with respect to 
their processing conditions is presented in Table 1.  
Manufacturing Eudragit RL/RS tablets via IM was possible across a broad temperature range, 
however, as one of the main disadvantages of hot melt processing involves thermal stability, 
the production temperature was kept as low as possible to avoid degradation of drug and 
carrier. Previous studies have reported that Eudragit RL and RS are thermostable up to 
167°C, and metoprolol is stable below 160°C, the process temperatures selected in this study 
were always below the onset of degradation of each component (18, 3). In addition, DSC 
measurements were conducted up to 180°C on individual components and physical 
mixtures, and no evidence of thermodegradation was found in all thermograms.  
Plasticizers are often included in IM formulations to improve flexibility and workability, as 
this allows lower production temperatures due to a decrease in melt viscosity and shear 
forces. In this study, the suitability of triethyl citrate (TEC) was assessed on processability 
and drug release. As seen in Table 1, increasing the TEC concentration in the formulations 
allowed considerably lower production temperatures and injection pressures. However, 10 
and 20% w/w TEC caused stability problems, as these tablets became gradually 
opaque/white during storage and were severely deformed after 1-year storage. These 
findings clearly indicated overplasticization, which was confirmed by DSC-measurements. 
Eudragit RL plasticized with 5, 10 or 20% w/p TEC had a Tg of 43.6, 37.7 and 22.8°C, 
respectively. This low glass transition temperature close to room temperature allowed the 
polymer chains to re-arrange due to increased mobility, resulting in sticky and opaque 
tablets and was responsible for the extensive deformation during storage. Thermal analysis 
(see section 3.2.2.) revealed that the conversion from transparent to opaque tablets was 
caused by a progressive recrystallization over time of the drug in the matrix, which was 
strongly influenced by the type of metoprolol salt. 
Formulations containing low concentrations of metoprolol salts (10-20%) required 
processing around their respective melting point to ensure sufficient plasticization of the 
material, whereas higher drug concentrations (30-40%) allowed processing at lower 
temperatures indicating a plasticizing effect of the drug on the polymer (Table 1). Solid-state 
plasticisation of polymers by pharmaceutically active agents has been previously reported 
during melt processing: the high level of mixing between molten polymer and drug and the 
elevated temperatures involved in extrusion facilitate intimate mixing between the two 
components, and can result in drug/polymer interactions allowing drug to occupy active 
sites along the polymer chain reducing polymeric inter-chain interactions, hence leading to 
reduced processing temperatures (7, 11). This is also reflected in a decreased glass transition 
temperature of the polymer (see section 3.2.2. for a more detailed discussion). 
Processing of these formulations resulted in the formation of transparent tablets, only 
tablets containing 40% MPS were opaque immediately after production. However, IM 
tablets containing 20, 30 and 40% w/w MPS, and 40 % MPF gradually became opaque during 
two months storage. After 1-year storage, only a limited number of IM tablets remained 
transparent (Table 1). SEM images showed a smooth surface indicating a good coalescence 
of the melt after cooling (data not presented).  To characterize the changes during storage 
and the interactions of metoprolol salts with Eudragit, the solid-state properties of these 
formulations were further analysed. 
 
3.2 Physicochemical properties and solid-state structure of injection-moulded tablets 
3.2.1 Solubility parameter calculation 
Estimation of the solubility parameters is commonly done to predict the miscibility of drug 
and excipients. The solubility parameter is a measure of the cohesive energy densities of 
materials (19). Greenhalg et al. (1999) suggested that interactions between polar groups (δp) 
and hydrogen bonding (δh) significantly affect solubility and should be incorporated into the 
estimation of the total solubility parameter, which previously only accounted for dispersive 
forces (δd). As a consequence, most applications use the group contribution method 
described by Van Krevelen to determine the Hansen partial solubility parameter, that allows 
for an improved characterisation of more polar molecules (20). This method makes use of 
specific functional groups present in the molecular structure of the molecules under 
investigation to calculate the sum of intermolecular forces that form cohesive energy. 
Cohesive energy is the net effect of different types of intermolecular interactions, such as 
Intermolecular or Van der Waals (dispersion) forces (δd), intermolecular polar forces (δp), 
and intermolecular hydrogen bonding (δh), and holds a substance together. By separate 
consideration of the sum of intermolecular forces, the ability of a molecule to interact with 
another one can be calculated. An overview of the solubility parameters is presented in 
Table 2. The difference between the solubility parameters of two materials gives an 
estimation of the likelihood that these components will be miscible. Components with 
similar solubility parameters are likely to be miscible (∆δt < 7MPa½) and components with ∆δt 
> 10MPa½ are likely to be immiscible. This is because the energy of mixing released by 
interactions within the component is balanced by the energy released by interactions 
between the components (20). All drug salts have similar solubility parameters and there is a 
high similarity in intermolecular dispersion forces and intermolecular hydrogen bonding 
between all drug salts and Eudragit RL and RS (Table 2). As the difference in total solubility 
parameter is less than 4 MPa½ for all drug/polymer mixtures, these compounds show 
miscibility and are expected to form one-phase solid solutions, which were already observed 
via the formation of transparent tablets immediately after IM (21).  
 
3.2.2 Thermal analysis of binary mixtures and injection-moulded samples 
Thermal analysis was performed to ascertain miscibility between drug and matrix carrier, 
and to further elucidate the solid-state properties of injection-moulded samples. Thermal 
analysis also provided evidence for miscibility between Eudragit RL and all metoprolol salts 
(Table 3): the melt onset temperature and heat of fusion decreased at higher Eudragit RL 
concentrations (22). In addition, independent of the metoprolol concentration and salt, part 
of the drug fraction dissolved in the polymer at temperature much lower than the melting 
point of the pure drug. These findings were confirmed using hot-stage microscopy, 
demonstrating that drug crystals were solubilized in the rubbery polymer below their 
respective melting point (Figure 1).  
In addition, DSC of binary mixtures showed a single Tg positioned between the glass 
transition temperatures of both components, indicating complete miscibility of drug and 
polymer at the given concentrations (23, 24).  
Although injection-moulded tablets were produced at temperatures below the melting point 
of the drug, a single Tg (data not presented) between the Tg of drug and carrier was also 
observed during thermo-analysis of the IM tablet. These findings illustrated that glass 
solutions of the drug were formed at production temperatures below the melting point of 
the metoprolol salt, due to the intensive mixing and high shear rates involved in the process, 
facilitating mixing and dispersion of drug and carrier at the molecular level.  
At low drug concentrations (10-20% w/w) the experimental glass transition data 
corresponded with the theoretical values calculated by the Gordon-Taylor equation, 
however, for higher drug concentrations negative deviations were observed, indicating a 
possible interaction between MP salts and Eudragit (Table 3). The Gordon-Taylor equation is 
a theoretical approach to predict the Tg of binary drug/polymer mixtures of ideal amorphous 
one-phase systems. According to this equation, if the drug and polymer are miscible, the 
mixture will show a single Tg that ranges between the Tg of pure components and depends 
on the relative proportion of each component (weight fraction). The negative deviation 
observed at higher metoprolol concentration could be attributed to a plasticizing effect of 
drugs on the polymer, resulting in a change of free volume of the system (14). This 
plasticizing effect of the different metoprolol salts on Eudragit was also evident from the 
glass transition temperatures (Table 3): a higher drug concentration in the physical mixtures 
lowered the glass transition temperature, demonstrating a solid-state plasticizing effect of 
drug on Eudragit.  
These results were confirmed by dynamical mechanical analysis of injection-moulded bars, 
showing a clear reduction in Tg for increasing drug concentrations irrespective of the type of 
drug (Figure 2). In addition, the type of metoprolol salt had a small influence on the Tg 
reduction, and similar results were obtained for Eudragit RS (data not shown). Glaessl et al. 
(2009) suggested that hydrophobic interactions between metoprolol base and the 
polymethacrylate backbone and/or ionic interactions between the different anions and the 
quaternary ammonium groups could possibly be the reason for this plasticizing effect (25). In 
this regard, Raman and NIR spectroscopy measurements were conducted to investigate 
more thoroughly the nature of these drug-polymer interactions. 
 
3.2.3 NIR and Raman spectroscopy 
The NIR spectra of the extrudates and IM tablets (Figure 3) manifested a broad peak around 
6500 cm-1 (1538 nm), which was absent in the spectra of physical mixtures. As hydrogen-
bonded hydroxyl groups induce a broad peak in the 6850 – 6240 cm-1 region (which has been 
attributed to the first overtone of the bonded hydroxyl (26)), this observation indicated that 
hydrogen bonds were formed between drug and polymer during thermal processing, where 
the hydroxyl groups of the metoprolol salts act as proton donors. The intensity of this H-
bond peak depended on the metoprolol salt, being the most intense in case of MPS and 
nearly non-existent for MPT, suggesting that the level of interaction between Eudragit RL 
and metoprolol was defined by the salt form (MPS>MPF>MPT). Interestingly, a correlation 
could be established between the extent of the hydrogen bonding and the glass transition 
temperature of these formulations, as the plasticizing effect of MPS on Eudragit was higher 
compared to MPF and MPT (Table 3, Fig. 4). Similar results were established at a lower 
processing temperature (120°C), a lower metoprolol salt concentration (10%) and using 
Eudragit® RS PO as matrix former. It should be noted that also hydrophobic and ionic 
interactions between the various metoprolol salts and the quaternary ammonium group 
present in the acrylic backbone of the polymer are likely to occur (25). 
In the Raman spectra peak shifts larger than 4 cm-1 occurred only for extruded and IM 
mixtures processed at 140°C and containing a 40% drug loading. These peak shifts were 
more pronounced for formulations processes at 140°C when compared with formulations 
processed at 120°C, indicating that polymer-drug interactions were more pronounced when 
higher processing temperatures were used. At higher manufacturing temperatures: the 
decrease in melt viscosity, increase in polymer free volume and mobility could enhance the 
formation of H-bonds between the polymer backbone and the metoprolol salt.  
As the peak shifts were only observed after thermal processing of the formulations, the 
molecular interactions and plasticizing effect of metoprolol salts on Eudragit polymers was 
also confirmed via Raman spectroscopy. The largest peak shifts were found in the spectra of 
MPS-containing tablets, highlighting the stronger plasticizing effect of the succinate anion on 
Eudragit (data not presented). 
 
3.2.4 X-ray diffraction 
Diffractograms of Eudragit RL, metoprolol tartrate, physical mixtures and IM samples are 
displayed in Figure 4. Metoprolol tartrate showed distinctive peaks due to its crystalline 
nature, whereas Eudragit RL was amorphous. Peaks corresponding to crystalline metoprolol 
tartrate were present in the physical mixture, however, absent in the diffractograms of 
transparent injection-moulded tablets produced at 120 and 140°C. This demonstrated that 
the drug is present in an amorphous state in IM samples and confirmed the DSC results. 
Similar results were obtained for metoprolol succinate and fumarate (data not shown). 
 
3.2.5. Storage stability 
Visual inspection of moulded samples revealed that some transparent tablets gradually 
turned cloudy/opaque during 1 year storage at ambient conditions (Table 1). Evidence of 
recrystallization was found in these formulations as a melting peak of metoprolol was 
observed during thermo-analysis. The percentage of amorphous drug that had reverted to 
the crystalline state was estimated from the heat of fusion of similar physical mixtures (Table 
4). Metoprolol tartrate provided the most stable formulations, as no recrystallization was 
observed during storage, even at high drug loadings. These formulations did not exhibit a 
melting transition and a single Tg was detected. In contrast, IM tablets containing metoprolol 
succinate and fumarate tended to recrystallize at higher drug load drug. These tablets 
possessed a melting endotherm and 2 glass transitions, indicating phase separation. These 
results suggested that molecular interactions between metoprolol salt and the methacrylate 
polymer have a significant impact in preventing drug recrystallization. These findings were 
confirmed with XRD-measurements (data not shown).   
 
3.3 In vitro drug release 
3.3.1. Influence of matrix composition and production temperature on drug release 
Figure 5 present the drug release profiles of matrix tablets containing Eudragit RL or RS and 
30% MPT. Both polymers have structurally the same composition but contain a different 
concentration of ammonium methacrylate units: Eudragit RL has approximately 5% (w/w, on 
dry substance), whereas Eudragit RL has 10%. Complete drug release was seen for all 
formulations after 24h of dissolution, following time-dependent release kinetics. Drug 
release from tablets based on Eudragit RL was faster compared to Eudragit RS-based tablets. 
By blending Eudragit RL and RS (ratio 1:1), intermediate drug release profiles were obtained, 
indicating that drug release can be tailored using both methacrylates (data not shown).  
These difference in drug release are most likely attributed to the different amounts of 
quaternary ammonium groups, which account for differences in water-permeability and 
hence dissolution properties. A matrix structure that is less water-permeable retards water 
influx and as a consequence drug dissolution and diffusion. The water-uptake of matrices 
containing Eudragit RL (±315% after 24h) was almost 5 times higher than Eudragit RS based 
tablets (±66% after 24h) (Figure 6). The radial swelling of Eudragit RS-based tablets was 
limited compared to Eudragit RL.  For both Eudragit grades no significant erosion of the IM 
tablets was observed during dissolution. The drug release data provided a good fit with the 
Ritger-Peppas model and anomalous transport was depicted as the main drug release 
mechanism, confirming that both diffusion and swelling contributed to the overall drug 
release process.  
In contrast to previous findings, using EC as matrix for IM tablets (2-5), the production 
temperature did not affect release from Eudragit-based tablets. As a higher production 
temperature reduced the polymer free-volume of the water-insoluble ethylcellulose and 
resulted in a denser and more tortuous matrix structure, drug release from EC matrices was 
incomplete and required a drug release modifying agent to promote drug release. In 
contrast, drug release from polymethacrylate-based tablets was complete due to their 
inherent water-permeability, allowing drug diffusion to occur through the hydrated 
polymeric network. This was confirmed by Carli et al. who reported that drug release form 
Eudragit RL or RS based systems was controlled by intraparticle diffusion (27).  
Drug release from matrix tablets based on Eudragit RL and RS was not affected by TEC 
content (0-10%).  
 
3.3.2 Influence of drug type and concentration on drug release 
The drug release profiles from Eudragit RL and RS formulations as a function of metoprolol 
concentration are presented in Figure 7. In case of Eudragit RL (Figure 7a), drug release was 
independent of drug loading. In contrast, tablets formulated with Eudragit RS showed faster 
drug release rates at higher MTP loading (Figure 7b). Only formulations containing 30 and 
40% MPT had a complete drug release, whereas only 77% and 30% MPT was released after 
24h dissolution from tablets containing 20 and 10% MPT, respectively. For Eudragit RS-based 
tablets, higher drug loadings also resulted in a more pronounced burst release. The water-
uptake from tablets containing 30% MPT was considerably higher compared to tablets with 
10% MPT, especially during the first 8 hours (Figure 6), but the difference in swelling was 
limited. As a result, leaching of the highly soluble drug from the matrix towards the 
dissolution medium could have made the matrix more accessible to the dissolution medium 
by creating additional pores in the matrix structure. The impact of pore formation on drug 
dissolution is higher for Eudragit RS-based systems which are inherently less water 
permeable compared to Eudragit RL tablets, hence the effect of drug content on drug 
release from Eudragit RS tablets as more channel formation occurred at higher drug content.  
To investigate the influence of metoprolol salts on drug release, IM tablets containing 30% 
w/w metoprolol tartrate, fumarate and succinate were prepared. For both methacrylates, 
tablets composed of metoprolol tartrate provided the fastest drug release rates, whereas 
drug release from metoprolol fumarate was the slowest (Figure 8). However, this difference 
in drug release was more pronounced for Eudragit RS-based tablets. In case of Eudragit RS 
formulations, only metoprolol tartrate was completely released after 24h dissolution, 
whereas metoprolol succinate and fumarate release was only 88 and 68% after 24h 
dissolution. These differences can not only be attributed to differences in intrinsic water 
solubilities (aqueous solubility at 37°C of metoprolol tartrate, fumarate and succinate is 
3630, 472 and 276 mg/ml, respectively) (28, 29), since metoprolol fumarate is more water-
soluble than metoprolol succinate but provided slower release rates. However, it was 
reported that in the presence of anions, the chloride counterion of the quaternary 
ammonium group exchanged with these anions affecting the permeability of the polymer 
and hence the drug release profile (30). In addition, Wagner et al. (2002) demonstrated that 
the degree of polymer swelling and the permeability-enhancing effect depended on both the 
concentration and type of anions exchanging with chloride (31). From the results obtained in 
the current study (Figure 8), faster drug release rates were seen for tartrate > succinate > 
fumarate. These anions exchanged with the chloride counterion and altered the 
permeability of the tablet and thus its hydratation, resulting in different release rates.   
 
3.4 Metoprolol tartrate bioavailability 
Oral administration of IM tablets containing 30% MPT and 70% Eudragit RS (formulation F1) 
resulted in significantly lower pharmacokinetic parameters compared to the reference 
formulation (Figure 9, Table 5), yielding a relative bioavailability of only 42%. Intact tablets 
(which still contained 30.7 ± 8.4% of the MPT dose) were found in the faeces of the dogs, the 
low BA probably resulted from the fast GI transit time in dogs in combination with the 
limited fluids in the dog GI tract (thus limiting drug diffusion from these matrix tablets). To 
overcome these limitations, oral administration of a formulation containing a higher drug 
load (50/50% MPT/Eudragit RS, formulation F2) and having a faster in vitro drug release rate 
was also evaluated (100% release after 4h), yielded similar pharmaco-kinetic parameters as 
reference formulation (Figure 9, Table 5), resulting in a relative bioavailability of 130%. Intact 
tablets were found in the faeces, but only 6.5 ± 2.5% of the initial dose MPT was recovered 
from these tablets, as the high drug load of these tablets promoted drug diffusion during 
passage in the GI tract.  
4. Conclusion 
Despite being widely used in the plastic processing industry, injection moulding is a relative 
new technique to the pharmaceutical industry. The possibility of a continuous operation 
system with limited process processing steps, automation, and reduction in labor cost 
demonstrate that injection moulding is a versatile and promising production technology. 
This study showed that sustained release matrix tablets based on Eudragit RL and/or RS 
were successfully produced by means of injection-moulding to control the drug release of 
different metoprolol salts. The drug release could be modulated by varying the matrix 
composition whereas the production temperature and plasticizer level did not affect drug 
release. All formulations showed first-order release kinetics and drug was released via a 
combination of swelling and diffusion (anomalous transport). The study showed that the 
metoprolol salt form had an impact on drug release, due to changes in matrix hydratation 
and permeability. Solubility parameters, thermal analysis, hot-stage microscopy and XRD 
ascertained that solid solution were formed after injection moulding, however, tablets 
containing high concentrations of metoprolol succinate and fumarate were not stable during 
storage, and re-crystallisation of the amorphous drug was seen. Metoprolol salts functioned 
as plasticizers for Eudragit RL/ RS, allowing lower processing temperatures thus making the 
process more economical in terms of energy input. However, when the glass transition 
temperature was too low Drug polymer interactions involved in these IM tablets included 
hydrophobic interactions, ionic interactions and H-bonding, offering valuable insights in the 
manufacturing of these dosage forms via hot-melt processing. The in vivo performance of 
injection moulded tablets depended on the drug dose, only in case of 50% MPT adequate 
drug plasma levels were observed. 
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